People · Operator
Named in public records as an officer, director or promoter · active 2020–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Eterna Therapeutics Inc. | — | Biotechnology | Series A | $53.1M | $26.6M | 2022 |
| Cytovia Holdings, Inc. | — | Biotechnology | Series A | $11.5M | $12.8M | 2023 |
| Exacis Biotherapeutics Inc. | — | Biotechnology | Seed | $1.1M | $42.2M | 2020 |
Gregory Fiore at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gregory Fiore on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Matthew Angel | 2 | 5 |
| Wei Li | 1 | 7 |
| Andrew Jackson | 1 | 4 |
| Michael Friedman | 1 | 4 |
| Thomas Robinson | 1 | 3 |
| Charles Cherington | 1 | 3 |
| Richard W. Wagner | 1 | 3 |
| MICHAEL NOONAN | 1 | 3 |
| STEVE MITGANG | 1 | 2 |
| Erin S. Enright | 1 | 2 |
| Jeff Berg | 1 | 2 |
| James Bristol | 1 | 2 |
| Kendra Berger | 1 | 2 |
| Heather B. Redman | 1 | 2 |
| TONY UPHOFF | 1 | 1 |
| PAUL YANOVER | 1 | 1 |
| Terry Bateman | 1 | 1 |
| KIRK NAGAMINE | 1 | 1 |
| Mary Beth Lewis | 1 | 1 |
| BARRY CHANDLER | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.